Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ALG$144.53-1.65(-1.13%)ALAMO GROUP INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS CONFERENCE CALL Alamo Group Inc. (NYSE: ALG) today announced that it will release financial results for the third quarter of 2026 after the market closes on Monday,...[4:15:00 PM ET]BAC$50.56-0.01(-0.01%)Bank of America, Blackstone, Citi and Morgan Stanley Announce Landmark $63 Billion Financing Structure to Enable AI Compute Capacity in Partnership with Broadcom Bank of America (NYSE: BAC), Blackstone (NYSE: BX), Citi (NYSE: C) and Morgan Stanley (NYSE: MS) (the "Lead Financial Partners") today announced a...[4:15:00 PM ET]LION$12.14-0.35(-2.80%)Lionsgate and Steven Paul's SP Media Launch New Joint Venture Lionsgate (NYSE: LION) and SP Media, led by longtime producer, financier and entrepreneur Steven Paul, today announced the formation of a joint...[4:15:00 PM ET]ALB$93.42-0.25(-0.27%)Albemarle Announces Quarterly Common Stock Dividend The Board of Directors of Albemarle Corporation (NYSE: ALB) today announced that it declared a quarterly common stock dividend of $0.41 per share....[4:15:00 PM ET]SXI$241.84+1.37(+0.57%)STANDEX ANNOUNCES APPOINTMENT OF BRENNA PREISSER TO BOARD OF DIRECTORS Standex International Corporation (NYSE: SXI), a leading manufacturer of highly engineered components and systems, today announced that its Board of...[4:15:00 PM ET]SSD$181.99-2.37(-1.29%)Simpson Manufacturing Co., Inc. Announces 2026 Third Quarter Financial Results and Updates 2026 Guidance Simpson Manufacturing Co., Inc. (the "Company") (NYSE: SSD), an industry leader in engineered structural connectors and building solutions, today...[4:15:00 PM ET]AZZ$133.39+1.03(+0.78%)AZZ Inc. Announces November Investor Conference and Non-Deal Roadshow Schedule AZZ Inc. (NYSE: AZZ), the leading independent provider of hot-dip galvanizing and coil coating solutions in North America, today announced its...[4:15:00 PM ET]PECO$39.00+0.64(+1.67%)Phillips Edison & Company Reports Third Quarter 2026 Results[4:14:25 PM ET]PARK$19.39-0.46(-2.32%)Park Dental Partners Announces Dates for Third Quarter 2026 Earnings Release and Conference Call[4:13:00 PM ET]LYCA$28.85-1.15(-3.83%)Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares[4:12:29 PM ET]AVBH$32.12+0.42(+1.32%)Avidbank Holdings, Inc. Announces Financial Results for the Third Quarter of 2026[4:11:00 PM ET]SRBK$19.02+0.14(+0.72%)SR BANCORP, INC. ANNOUNCES FINANCIAL RESULTS SR Bancorp, Inc. (the "Company") (NASDAQ: SRBK), the holding company for Somerset Regal Bank (the "Bank"), announced net income increased 54.1% to $1....[4:10:00 PM ET]HWKN$149.69+17.37(+13.13%)Hawkins, Inc. Reports Second Quarter Fiscal 2027 Results[4:10:00 PM ET]ARE$43.40+0.38(+0.88%)Alexandria Real Estate Equities, Inc. Reports 3Q26 and YTD 3Q26 Net Loss per Share - Diluted of $3.74 and $2.06, respectively, and 3Q26 and YTD 3Q26 FFO per Share - Diluted, as Adjusted, of $1.54 and $5.00, respectively Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced financial and operating results for the third quarter ended September 30, 2026. KEY...[4:10:00 PM ET]ZDGE$2.74+0.03(+1.11%)Zedge Reports Fourth Quarter and Full-Year Fiscal 2026 Results[4:10:00 PM ET]LWLG$4.09+0.08(+2.00%)Lightwave Logic, Inc. Announces Timing of Third Quarter 2026 Financial Results and Business Update Call[4:10:00 PM ET]

XNCR · NASDAQ

Xencor, Inc.

$29.00 +3.82 (+15.17%)

Company overview

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Xencor develops Plamotamab, a tumor-targeted antibody in Phase I clinical trial for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab in Phase II clinical trial for neuroendocrine tumors.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.2B
Employees
250
Headquarters
Pasadena, CA
Website
xencor.com
CEO
Bassil I. Dahiyat
Listed
December 3, 2013
P/E
-12.58
Dividend yield
0.00%

Company financials

Revenue
$97.4M
Gross profit
$89.6M
Operating income
-$212M
EBITDA
-$85.6M
Net income
-$172M
EPS
-$2.29
Total assets
$737M
Total debt
$175M
Gross margin
91.99%
Net margin
-177.10%
Earnings yield
-7.95%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No annual geographic segmentation.

Showing FY 2025

Price chart

9.5715.0320.4925.9631.42
XNCR 1D NASDAQ O25.52H25.81L24.42C25.18-0.66 (-2.55%)Vol1.46M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
XNCRXencor, Inc. Stock news Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway Seeking Alpha
XNCRXencor, Inc. Stock news Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer MarketBeat
XNCRXencor, Inc. Stock news Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript Seeking Alpha
XNCRXencor, Inc. Stock news Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst Benzinga
XNCRXencor, Inc. Press release Defining Moments in the Race for Biotech Breakthroughs GlobeNewswire
XNCRXencor, Inc. Stock news Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and GuruFocus
XNCRXencor, Inc. Press release Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors Business Wire
XNCRXencor, Inc. Press release Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Business Wire
XNCRXencor, Inc. Stock news Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast Defense World
XNCRXencor, Inc. Stock news Xencor to Present at the 2026 Cantor Global Healthcare Conference Business Wire
XNCRXencor, Inc. Stock news Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
XNCRXencor, Inc. Stock news Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? Zacks Investment Research
XNCRXencor, Inc. Press release Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Business Wire
XNCRXencor, Inc. Stock news Xencor: Bullish On Their Increasingly In-House Pipeline Seeking Alpha
XNCRXencor, Inc. Stock news The Biology Came First. GuruFocus
XNCRXencor, Inc. Stock news Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha
XNCRXencor, Inc. Stock news Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates Zacks Investment Research
XNCRXencor, Inc. Press release Xencor Reports First Quarter 2026 Financial Results Business Wire
XNCRXencor, Inc. Stock news Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript Seeking Alpha
XNCRXencor, Inc. Press release Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW Business Wire
See more
FAQ

Questions about Xencor, Inc.

What does Xencor, Inc. do?
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Xencor develops Plamotamab, a tumor-targeted antibody in Phase I clinical trial for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II clinical trial for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab in Phase II clinical trial for neuroendocrine tumors.
What is XNCR's market cap?
Xencor, Inc. (XNCR) is a listed stock with a live quote. The latest market cap on this page is $2.2B.
Where is Xencor, Inc. headquartered?
Xencor, Inc. is headquartered in Pasadena, CA.
How do I get XNCR news from the API?
Call GET /v1/news?tickers=XNCR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does XNCR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for XNCR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the XNCR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs